Table 6.

TEAEs leading to dose discontinuation

Dose disruption
Patient number (n = 9)Treatment group
Cohort no. or expansion (dose)
AE termAction taken with pralatrexateAction taken with CHOP
Expansion (30 mg/m2Anemia Drug withdrawn Drug withdrawn 
Cohort 5 (30 mg/m2Hypovolemic shock Drug withdrawn Drug withdrawn 
Expansion (30 mg/m2Neutrophil count decreased
Aspartate aminotransferase increased
Febrile neutropenia 
Drug withdrawn
Drug withdrawn
Drug withdrawn 
Drug withdrawn
Drug withdrawn
Drug withdrawn 
Expansion (30 mg/m2Mucosal inflammation Drug withdrawn Dose not changed 
Expansion (30 mg/m2Abdominal sepsis Drug withdrawn Drug withdrawn 
Cohort 5 (30 mg/m2Neutrophil count decreased Drug withdrawn Dose not changed 
Expansion (30 mg/m2Neutropenia Drug withdrawn Drug withdrawn 
Expansion (30 mg/m2Nausea Drug withdrawn Drug withdrawn 
Expansion (30 mg/m2Confusional state
Fatigue 
Drug withdrawn Drug withdrawn 
Dose disruption
Patient number (n = 9)Treatment group
Cohort no. or expansion (dose)
AE termAction taken with pralatrexateAction taken with CHOP
Expansion (30 mg/m2Anemia Drug withdrawn Drug withdrawn 
Cohort 5 (30 mg/m2Hypovolemic shock Drug withdrawn Drug withdrawn 
Expansion (30 mg/m2Neutrophil count decreased
Aspartate aminotransferase increased
Febrile neutropenia 
Drug withdrawn
Drug withdrawn
Drug withdrawn 
Drug withdrawn
Drug withdrawn
Drug withdrawn 
Expansion (30 mg/m2Mucosal inflammation Drug withdrawn Dose not changed 
Expansion (30 mg/m2Abdominal sepsis Drug withdrawn Drug withdrawn 
Cohort 5 (30 mg/m2Neutrophil count decreased Drug withdrawn Dose not changed 
Expansion (30 mg/m2Neutropenia Drug withdrawn Drug withdrawn 
Expansion (30 mg/m2Nausea Drug withdrawn Drug withdrawn 
Expansion (30 mg/m2Confusional state
Fatigue 
Drug withdrawn Drug withdrawn 

or Create an Account

Close Modal
Close Modal